WELLIN

Insights / Solid-tumour CAR-T

The first international patient treated with a solid-tumour CAR-T in China: what families should know

Reports from Shanghai describe a New Zealand patient’s treatment with satri-cel. This is one case, with continued follow-up, rather than a promise of results for other patients.

WELLIN Patient Care Team. Updated 29 October 2026.

What was approved

China approved satri-cel in June 2026 as the first CAR-T therapy for a solid tumour. Its approved indication is advanced gastric or gastro-oesophageal junction adenocarcinoma that is CLDN18.2-positive and HER2-negative, after at least two lines of treatment have failed. The approval does not cover every solid tumour.

The reported patient journey

The reports describe “Josh”, a 59-year-old from New Zealand diagnosed with advanced gastroduodenal adenocarcinoma in late 2025. His disease progressed despite chemotherapy combined with immunotherapy. On 6 July 2026, his T cells were collected at Jiahui International Cancer Center in Shanghai.

SmartShanghai reports that before infusion, malignant ascites required drainage of about 1,000 mL daily, peaking at 2,000 mL. By day 10 after infusion, the ascites had resolved, the drainage catheter was removed and he was discharged. He returned to New Zealand and continued follow-up.

What a family can take from this

This is a single reported case. It does not establish the response, safety or long-term outcome another patient will have. Discharge and improvement in ascites are not a guarantee of lasting disease control.

The treating hospital must assess whether a patient is suitable, including the diagnosis, biomarker results, previous treatments and current condition. A family should ask the hospital what further records or tests it needs, what risks and alternatives apply, and how follow-up would work after returning home.

This article summarises the three reports below; it does not describe a case arranged by WELLIN. For general background, see CAR-T therapy in China and asking for a specialist opinion.

Sources

Information for patients and families, not an individual treatment recommendation. Prepared with AI assistance.